🔎 Trials Near Me

Beranda › Kanker Ginjal (Karsinoma Sel Renal) › Georgia

Uji klinis Kanker Ginjal (Karsinoma Sel Renal) di Georgia

12 studi untuk Kanker Ginjal (Karsinoma Sel Renal) mencari peserta di lokasi di Georgia.

Kota di Georgia

Teks studi resmi (Bahasa Inggris)

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

  • Research Site, Atlanta
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT05536141

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • Winship Cancer Institute of Emory University, Atlanta
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06270706

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Northeast Georgia Medical Center Braselton, Braselton
  • Atlanta VA Medical Center, Decatur
  • Northeast Georgia Medical Center-Gainesville, Gainesville
  • dan 4 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT03866382

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
  • Emory Saint Joseph's Hospital, Atlanta
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT04981509

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102), Marietta
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07489495

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  • Tennessee Oncology, PLLC- Ringgold, Ringgold
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07227415

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  • Grady Health System, Atlanta
  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
  • dan 2 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06661720

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

  • Emory University - Winship Cancer Institute, Atlanta
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT06582017

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, Atlanta
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT05433142

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Winship Cancer Institute - Emory University, Atlanta
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT04198766

A Beta-only IL-2 ImmunoTherapY Study

  • Emory - Winship Cancer Institute, Atlanta
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2025 · NCT05086692

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.